Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia-Reference-Cited by-同舟云学术

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

Published:2014-08-28 Issue:9 Volume:124 Page:1460-1472
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kiel Mark J.¹,Velusamy Thirunavukkarasu¹,Rolland Delphine¹,Sahasrabuddhe Anagh A.¹,Chung Fuzon¹,Bailey Nathanael G.¹,Schrader Alexandra²,Li Bo³,Li Jun Z.³⁴,Ozel Ayse B.⁴,Betz Bryan L.¹,Miranda Roberto N.⁵,Medeiros L. Jeffrey⁵,Zhao Lili⁶,Herling Marco²,Lim Megan S.¹,Elenitoba-Johnson Kojo S. J.¹

Affiliation:

1. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI;

2. Laboratory of Lymphocyte Signaling and Oncoproteome, Department of Medicine, University of Cologne, Cologne, Germany;

3. Department of Computational Medicine and Bioinformatics and

4. Department of Human Genetics, University of Michigan, Ann Arbor, MI;

5. The University of Texas MD Anderson Cancer Center, Houston, TX; and

6. Department of Biostatistics, University of Michigan Medical School, Ann Arbor, MI

Abstract

Key Points We identify gain-of-function mutations involving IL2RG, JAK1/3, and STAT5B as well as deleterious mutations affecting EZH2, FBXW10, and CHEK2 in T-PLL. Pharmacologic targeting of primary T-PLL cells with the STAT5 inhibitor pimozide leads to apoptosis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/9/1460/1383231/1460.pdf

Reference50 articles.

1. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia.;Matutes;Blood,1991

2. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.;Hopfinger;Cancer,2013

3. T-cell prolymphocytic leukemia.;Dearden;Clin Lymphoma Myeloma

4. Identification of the TCL1 gene involved in T-cell malignancies.;Virgilio;Proc Natl Acad Sci USA,1994

5. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes.;Pekarsky;Proc Natl Acad Sci USA,1999

Cited by 208 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and genetic profile of Chinese patients with indolent natural killer-cell lymphoproliferative disorder of the gastrointestinal tract;Neoplasia;2024-11

2. Sequential mosaic variants inKRASandSTAT5Bassociated with a mixed phenotype of two acquired errors of immunity;2024-08-08

3. The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain;Proceedings of the National Academy of Sciences;2024-07-16

4. Morphology, immunophenotype, and suggested diagnostic criteria of TCL1 family–negative T-prolymphocytic leukemia;American Journal of Clinical Pathology;2024-06-30

5. A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia;Blood;2024-06-13